The main objective of WP3 is to identify metabolite signatures specific for different forms of endocrine hypertension with further exploration for stratifying patients with essential hypertension. Since the metabolome reflects the outcome of activity of different cellular processes, this WP provides functional relevance to the omics information provided by WP2. These data will add to the omics bioinformatics data analyses to be undertaken in WP1, with the further objective of validating omic patterns (the SIGNATURE) in a prospectively screened population of hypertensive patients, recruited under WP4, according to defined outcome measures as well as additional economic evaluations in WP5. The underlying hypothesis is that omics-derived strategies directed at endocrine forms of hypertension provide a means, not only for improved diagnosis of such patients, but more importantly for stratifying primary forms of hypertension for cost-effective therapy according to personalised assessments of risk for end-organ damage.
The main objective of WP3, which will facilitate addressing this hypothesis, will be reached through 3 specific aims:
- Characterise metabolome profiles in plasma and urine from patients with endocrine hypertension.
- Establish a panel of low molecular weight biomarkers for high-throughput LC-MS/MS screening to identify patients with endocrine hypertension.
- Identify different subgroups of patients with essential hypertension according to patterns in omics signatures and from this define a panel of low molecular weight biomarkers to stratify hypertensive patients according to these signatures.